Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – bupropion

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Bupropion Testmiljö

Bupropion

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Turner E, Jones M, Vaz LR, Coleman T. Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. Nicotine Tob Res. 2019;21(8):1001-1010.

  2. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932-936.

  3. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474-84.

  4. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf. 2014;23(10):1066-75.

  5. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203:52e1-6.

  6. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-407.

  7. Tran DT, Preen DB, Einarsdottir K, Kemp-Casey A, Randall D, Jorm LR et al. Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Med. 2020;18(1):15.

  8. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;3(3):CD010078.

  9. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138:.

  10. Rotem-Kohavi N, Williams LJ, Virji-Babul N, Bjornson BH, Brain U, Werker JF et al. Alterations in Resting-State Networks Following In Utero Selective Serotonin Reuptake Inhibitor Exposure in the Neonatal Brain. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4(1):39-49.

  11. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142-51.

  1. Turner E, Jones M, Vaz LR, Coleman T. Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. Nicotine Tob Res. 2019;21(8):1001-1010.
  2. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932-936.
  3. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474-84.
  4. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf. 2014;23(10):1066-75.
  5. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203:52e1-6.
  6. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-407.
  7. Tran DT, Preen DB, Einarsdottir K, Kemp-Casey A, Randall D, Jorm LR et al. Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Med. 2020;18(1):15.
  8. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;3(3):CD010078.
  9. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138:.
  10. Rotem-Kohavi N, Williams LJ, Virji-Babul N, Bjornson BH, Brain U, Werker JF et al. Alterations in Resting-State Networks Following In Utero Selective Serotonin Reuptake Inhibitor Exposure in the Neonatal Brain. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4(1):39-49.
  11. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142-51.